Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject: A survey among Indian healthcare practitioners to understand In-Practice usage of mirabegron in management of Neurogenic Lower Urinary Tract Dysfunction

Individuals are diagnosed with overactive bladder (OAB) if they experience urinary urgency, usually with increased daytime frequency and nocturia, that is not caused by a proven infection or other obvious pathology. Pharmacotherapy options principally include antimuscarinics, including solifenacin, and the b3-adrenoreceptor agonist mirabegron.

The first-in-class b3-adrenoceptor agonist mirabegron is indicated for the management of OAB syndrome. Evidence for its use in this setting includes several large phase 3 trials. Compared with placebo, oral mirabegron for 12 weeks reduced the frequency of micturition and generally also that of incontinence, with other benefits including reduced urgency, increased void volume and improved health related quality-of-life (HR- QOL). In a 12-week powered comparison versus solifenacin in patients dissatisfied with antimuscarinic efficacy, mirabegron did not demonstrate noninferiority in reducing micturition frequency or significantly differ in terms of improving other urinary symptoms. Urinary and HR-QOL benefits of mirabegron were sustained over up to 52 weeks of treatment and the drug was generally well tolerated, with a numerically lower incidence of dry mouth than antimuscarinics. Real-world data support the trial findings and indicate possible persistence and adherence benefits for mirabegron over antimuscarinics. Current clinical evidence indicates that mirabegron provides an alternative to antimuscarinics for the management of OAB in adults, including those for whom antimuscarinics have proven unsuitable.

The current survey is planned among Indian healthcare practitioners to understand In- Practice usage of mirabegron in management of Neurogenic Lower Urinary Tract Dysfunction.

As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.